Finally, talazoparib is currently being tested in a phase 2 rial in combination with atezolizumab, to determine if this combination would be superior to atezolizumab maintenance in patients with extensive SCLC who have SLFN11-positive tumors (NCT04334941). This evidence concerns the gene SLFN11 and small cell lung carcinoma.